Novo Nordisk (NVO) shares have declined 59.6% over the past three years, prompting a debate on whether current valuations reflect the company's earnings power amidst shifting sentiment in diabetes and obesity treatments. The article analyzes the stock's valuation metrics, noting that Novo Nordisk trades at approximately 9.7x earnings, significantly lower than the Pharmaceuticals sector average of 20.6x and peer group averages near 33.9x. Analysts and community narratives suggest a divergence in fair value estimates for the Danish pharmaceutical giant. A bullish perspective argues that high barriers to entry, a booming obesity treatment market, and an expanding pipeline support a view that the stock is 70% undervalued. Conversely, a bearish narrative suggests current prices may already reflect mid-single-digit revenue growth through 2030, implying the stock could be 26% overvalued. The analysis highlights that while fresh trial data from rival Eli Lilly showing retatrutide outperforming Ozempic creates competitive pressure, Novo Nordisk's valuation remains discounted relative to its sector and peers. The article concludes that despite these external pressures and mixed community opinions on future growth trajectories, the current P/E ratio suggests the shares screen as undervalued based on historical data and fundamental analysis.